Home
RSSA new, oral type 2 diabetes medicine, Galvus has showed fewer side effects than present treatments. It stimulates pancreas to regulate blood sugar levels smoothly. Weight management is the key factor for the people to deal with diabetes.
Galvus has...
Related Stories
Most Recent
Most Popular
Most Commented
1
Star It 
(0)
AP, Whitehouse Station
Drugmaker Merck & Co. posts a 57 percent drop in first-quarter income due to a fall in both sales of its drugs and income from its partnership on cholesterol...
made popular Apr 21 2009
AP, New York
Schering-Plough Corp., in the process of being acquired by competitor Merck & Co., said Tuesday drug sales fell in the first quarter but profit tripled because of...
made popular Apr 21 2009
AP, New York
Schering-Plough, in the process of being acquired by competitor Merck, says drug sales fell in the first quarter but profit tripled because of a charge in last...
made popular Apr 21 2009
AP, Whitehouse Station
Merck & Co., a Dow component and the world’s No. 8 drug maker by revenue, reports earnings for the first quarter on Tuesday morning. The following is a...
made popular Apr 17 2009
AP, New York
Fears over shaky credit markets are baked into Merck’s $41.1 billion agreement to buy rival drugmaker Schering-Plough.
made popular Mar 10 2009
AP, New York
Wall Street managed an advance Monday after a drugmakers Merck and Schering-Plough announced a $41 billion deal.
made popular Mar 9 2009
AP, New York
Stocks were fluctuating Monday as a $41 billion deal between drugmakers Merck and Schering-Plough did little to jolt investors out of their pessimistic mood.
made popular Mar 9 2009
AP, New York
Stocks are falling as a $41 billion deal between drugmakers Merck and Schering-Plough does little to jolt investors out of their pessimistic mood.
made popular Mar 9 2009
AP, Whitehouse Station
Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash in a deal that gives the maker of asthma drug Singulair more firepower to compete...
made popular Mar 9 2009
AP, Whitehouse Station
Drugmakers Merck & Co. and Schering-Plough Corp., already partners in a joint venture, are planning to merge under the name Merck in a stock-and-cash deal worth...
made popular Mar 9 2009
AP, New York
Stock futures are pointing lower after drugmakers Merck and Schering-Plough announced a $41 billion cash-and-stock deal.
made popular Mar 9 2009
AP, Whitehouse Station
Drugmakers Merck & Co. and Schering-Plough Corp., already partners in a joint venture, are planning to merge under the name Merck in a stock-and-cash deal worth...
made popular Mar 9 2009
AP, New York
Merck & Co.’s chief executive, Richard T. Clark, received a compensation package valued at $17.3 million in 2008, up 20 percent from a year earlier,...
made popular Feb 26 2009
AP, Whitehouse Station
Drugmaker Merck & Co. swings to a fourth-quarter profit, despite lower sales, and beats Wall Street expectations.
made popular Feb 3 2009
AP, London
German drugmaker Merck Serono is one step closer to releasing the first pill to treat multiple sclerosis, the company said Friday.
made popular Jan 23 2009
AP, Trenton
Drugmaker Merck & Co. has asked federal regulators to approve use in males for its vaccine against the human papillomavirus, which causes cervical and other...
made popular Jan 6 2009
AP, Trenton
Schering-Plough Corp. says sales of the cholesterol drugs it markets with partner Merck & Co. have started dropping again.
made popular Dec 18 2008
AP, Whitehouse Station
Drugmaker Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research...
made popular Dec 9 2008
AP, Whitehouse Station
Drugmaker Merck & Co. tried to reassure investors Tuesday that its latest restructuring strategy will put the company back on a growth track as it moves into new...
made popular Dec 9 2008
All Stories
Most Recent
Most Popular
Most Commented
The U.S. Food and Drug Administration had accepted the oral therapy Galvus of Novartis for people with Type 2 diabetes for standard review, the Swiss drug firm said on...
made popular Mar 31 2006
Related Tags
Bank Leu blood sugar FDA Health & Fitness Merck Novartis Oral Diabetes Therapy type 2 diabetes U.S. Food and Drug Administratio Vildagliptin
